Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05277116 · ClinicalTrials.gov registry record · NA
The Electronic Medical Records and GEnomics (eMERGE) Network Genomic Risk Assessment
A NA study of Genetic Disease, sponsored by Vanderbilt University Medical Center.
- Active
- Registry status
- NA
- Development phase
- 26,877
- Enrollment target
- 12
- Study locations
NCT05277116 is a NA study of Genetic Disease that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 26,877 participants, above the 1,665-participant average among 30 other Genetic Disease trials with a reported enrollment target (1514% higher). The trial reports 12 study locations across 10 states.
The verdict
NCT05277116, a NA study of Genetic Disease, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 26,877 participants
- Enrollment target
- 12
- Study locations
Study Summary
The eMERGE Network embraces the opportunity to use new methods in genomic medicine, information science, and research participant engagement to identify people at very high risk for specific diseases and recommend individualized approaches to prevention and care. The investigators will conduct a prospective study, with diverse and underserved participants, across ten eMERGE study sites to evaluate clinical implementation of a Genome Informed Risk Assessment (GIRA) tool that combines genetic, family history, and clinical risk information from participants.
Conditions Studied
Interventions
- OTHER Genome Informed Risk Assessment (GIRA) report
Study Locations (12)
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
New York
- Mount Sinai - New York
- Columbia University - New York
Alabama
- University of Alabama Birmingham - Birmingham
Arizona
- Mountain Park Health Center - Tempe
Illinois
- Northwestern - Chicago
Minnesota
- Mayo Clinic - Rochester
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26,877 participants |
| Start Date | 2022-02-16 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05277116
The ClinicalTrials.gov registry entry for NCT05277116 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 26,877 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,665-participant average among 30 other Genetic Disease trials with a reported enrollment target (1514% higher). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Genetic Disease appearing as the primary indexed condition, and to 1 intervention - of which Genome Informed Risk Assessment (GIRA) report is the first listed.
NCT05277116 reports 12 study locations spanning 10 distinct geographic areas - top geographies include Massachusetts, New York, Alabama.
Frequently Asked Questions
What is clinical trial NCT05277116 about?
NCT05277116 is a clinical study titled "The Electronic Medical Records and GEnomics (eMERGE) Network Genomic Risk Assessment". The eMERGE Network embraces the opportunity to use new methods in genomic medicine, information science, and research participant engagement to identify people at very high risk for specific diseases and recommend individualized approaches to prevention and care. The investigators will conduct a pro...
What is the current status of trial NCT05277116?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 26,877 participants. The study started on 2022-02-16. Estimated completion is 2026-12-31.
What conditions does trial NCT05277116 study?
This clinical trial studies the following conditions: Genetic Disease.
What interventions are being tested in trial NCT05277116?
The interventions under investigation include: Genome Informed Risk Assessment (GIRA) report (OTHER).
Who is sponsoring clinical trial NCT05277116?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05277116 being conducted?
This trial has 12 study locations across Alabama, Arizona, Illinois, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genetic Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Adaptive Clinical Trial of BeginNGS Newborn Screening for Hundreds of Genetic Diseases by Genome Sequencing
RECRUITING · NA
-
Large Language Models To Improve the Quality of Care of Cardiology Patients
RECRUITING · NA
-
Grand Valley State University (GVSU) Skills on Wheels
ACTIVE NOT RECRUITING · NA
-
Clinical Decision Support to Identify Pediatric Patients With Undiagnosed Genetic Disease
ACTIVE NOT RECRUITING · NA
-
Overcoming Barriers to Accessing Genetic Medicine
ACTIVE NOT RECRUITING · NA
-
Pediatric Powered Wheelchair Standing Devices: An Exploratory Study
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.